/
DRMA
$1.30+$0.01 (+0.78%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Market cap
$5.2M
4M shares
52-week range
$1.10 – $8.00
3% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Borrow rate
38.43%
Hard to borrow
Price (6 mo)
Loading chart…
Change$-12454.70
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | $1.4K | $322 | $0 | $0 | $0 | $0 | $0 |
| Gross profit | −$1.4K | −$322 | $0 | $0 | $0 | $0 | $0 |
| Gross margin | — | — | — | — | — | — | — |
| R&D | $2.6M | $1.6M | $3.5M | $5.7M | $4.1M | $8.2M | $2.9M |
| Operating income | −$4.5M | −$3.2M | −$7.9M | −$9.7M | −$8.0M | −$12.5M | −$7.8M |
| EBITDA | −$4.5M | −$3.0M | −$7.9M | −$9.6M | $247.2K | −$12.3M | −$7.8M |
| Net income | −$4.7M | −$3.2M | −$7.9M | −$9.6M | −$7.8M | −$12.3M | −$7.6M |
| Net margin | — | — | — | — | — | — | — |
| EPS (diluted) | -95.50 | -932.64 | -152.70 | -139.20 | -399.81 | -80.32 | -8.16 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $100000 | $-2.21 | $-2.21–$-2.21 | 1 |
| 2027 | $750000 | $-1.52 | $-1.52–$-1.52 | 1 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$7.66
Price
$1.30
Implied upside
+489%
Peer comparison
Dermata Therapeutics, Inc. Common Stock
Dermata Therapeutics Inc develops and commercializes dermatology products for the treatment of common skin conditions. It focuses on leveraging prior clinical and technical expertise to develop OTC treatments for conditions such as acne, psoriasis, rosacea, and seborrheic dermatitis. The company is currently developing a once-weekly acne treatment system that utilizes an active ingredient from the OTC monograph in combination with the company's Spongilla technology. It intends to apply its Spongilla technology platform across a range of dermatologic and aesthetic skin applications, including intradermal delivery of botulinum toxin. The company's operates in one segment, which is the business of developing, branding, marketing, and commercializing direct to consumer skincare products.
www.dermatarx.com- Employees
- 9
- IPO / List date
- Aug 13, 2021
- HQ
- SAN DIEGO, CA
Held by traders on TradeandTell
No one on the platform currently holds DRMA.
Super investors & insiders
Institutions holding (13F)
No tracked institution reports a position in DRMA as of their last filing.
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2025-08-01 | 1-for-10reverse |
| 2024-05-16 | 1-for-15reverse |
| 2023-03-14 | 1-for-16reverse |
Recent trades on TradeandTell
No one on the platform has traded DRMA yet.
